The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 04, 2026
Dividend Yield: 4.32%
Annual Dividend: $2.51 per share
Payout Ratio: 69.7%
Ex-Dividend Date: 2026-07-02
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 55
Bristol-Myers Squibb Company dividend income comes from one of the largest biopharmaceutical companies in the world, with a portfolio spanning oncology, cardiovascular, and immunology treatments including Eliquis, Opdivo, and Revlimid. BMY currently yields 4.35%, placing it firmly in high-yield territory. The company pays quarterly, with a trailing annual dividend of $2.50 per share and the next ex-dividend date set for July 2, 2026. A beta of 0.238 means BMY stock moves far less than the broader market, which appeals to income-focused investors who prioritize low volatility.
Bristol-Myers Squibb Company pays out 69.7% of earnings as dividends, a payout ratio classified as elevated (60–75%). That level is supported by a broad commercial portfolio, including high-demand therapies like Eliquis for atrial fibrillation and Opdivo across multiple oncology indications, which generate recurring prescription revenue. Bristol-Myers Squibb Company dividend safety faces pressure from the fact that pharmaceutical revenue is tied to patent lifecycles, and the loss of exclusivity on key products can erode the earnings base that funds the payout.
Bristol-Myers Squibb Company dividend history shows a CAGR of 4.3% per year from 2006 to 2025. The per-share annual dividend grew from $1.12 to $2.48 over that period (2026 is a partial year and excluded from the CAGR calculation). The largest annual increase in the window was 39.6% in 2020, though the data also contains at least one year-over-year decline exceeding 5%, so growth has not been linear. Four consecutive years of increases bring the current streak, which is a short run by dividend-growth standards.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +4.7% | $2.16 (2022) | $2.48 (2025) |
| 5-Year | +1.6% | $2.29 (2020) | $2.48 (2025) |
| 10-Year | +5.2% | $1.49 (2015) | $2.48 (2025) |
Bristol-Myers Squibb Company fits income-focused investors who want a high yield from a large-cap biopharmaceutical business and can accept some payout risk. The current yield of 4.35% sits above the 5-year average of 3.75%, meaning the stock is paying out more relative to its price than it has historically. That yield classification is high (above 4%), which is the primary draw. The trade-off is a 69.7% payout ratio that leaves limited room for aggressive dividend growth, and a four-year increase streak that is short relative to the 55-year dividend history. BMY stock offers income now, with modest growth expectations.
| Payment Date | Amount per Share |
|---|---|
| 2026-07-02 | $0.6300 |
| 2026-04-02 | $0.6300 |
| 2026-01-02 | $0.6300 |
| 2025-10-03 | $0.6200 |
| 2025-07-03 | $0.6200 |
| 2025-04-04 | $0.6200 |
| 2025-01-03 | $0.6200 |
| 2024-10-04 | $0.6000 |
| 2024-07-05 | $0.6000 |
| 2024-04-04 | $0.6000 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.8900 |
| 2025 | $2.4800 |
| 2024 | $2.4000 |
| 2023 | $2.2800 |
| 2022 | $2.1600 |
Project income from BMY with the BMY dividend calculator or track your full portfolio with the dividend tracker.